Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna, Inc. MRNA reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

Moderna has asked the FDA for emergency use authorisation for a fourth dose of its mRNA COVID-19 vaccine SpikeVax ... Pfizer's application was from an open-label study in Israel involving ...

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...

Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial ...

Moderna has been rebuked by ... not be seen as anything other than promotion of Spikevax,” the PMCPA said. The presentation also included off-label data. Molly Kingsley, from the campaign ...

The lawsuit said, opens new tab Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger RNA into the human body.

According to Reuters, the company earned $6.7 billion in revenue from Spikevax in 2023. Moderna has stated in the past that it is “not aware of any significant intellectual property impediments ...